Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.

Breast cancer research and treatment - 1 Jan 2010

Abstract excerpt

Recent findings indicate a greater risk of postmenopausal breast cancer with estrogen-progestagen therapy than estrogen monotherapy, and more so for current than past use. Few studies have examined individual genetic susceptibility to the effects of menopausal hormone therapy. We used two population-based case-control studies with 3,155 postmenopausal breast cancer patients and 5,496 controls to evaluate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen Replacement Therapy
Share to Estrogens
Share to Gene Expression Regulation, Enzymologic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Germany

Share to Logistic Models

Share to Postmenopause

Share to Progestins

Share to Risk Assessment

Source

Identifiers

PMID: 19424794
DOI: 10.1007/s10549-009-0407-0

Genes

GSTT1
GSTP1
COMT
GSTM1
GSTM3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.PMID 19424794Read ↗

Estrogen metabolism genotypes, use of long-term hormone replacement therapy and risk of postmenopausal breast cancer.Semantic proximity Read ↗

Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.Semantic proximity Read ↗

Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk.Semantic proximity Read ↗

Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.Semantic proximity Read ↗

Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review.Semantic proximity Read ↗

Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk.Semantic proximity Read ↗

Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy.Semantic proximity Read ↗

Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.Semantic proximity Read ↗

Estrogen-related genes and their contribution to racial differences in breast cancer risk.Semantic proximity Read ↗

Pharmacogenetics and Regulation of Human Cytochrome<i>P</i>450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic InterventionSemantic proximity Read ↗

Polymorphisms of catechol estrogens metabolism pathway genes and breast cancer risk in Mexican women.Semantic proximity Read ↗

The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.